BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22989017)

  • 1. Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils.
    Förster A; Falcone FH; Gibbs BF; Preussner LM; Fiebig BS; Altunok H; Seeger JM; Cerny-Reiterer S; Rabenhorst A; Papenfuss K; Valent P; Kashkar H; Hartmann K
    Leuk Lymphoma; 2013 Apr; 54(4):835-42. PubMed ID: 22989017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
    Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
    Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation.
    Moriwaki K; Shinzaki S; Miyoshi E
    J Biol Chem; 2011 Dec; 286(50):43123-33. PubMed ID: 22027835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells.
    Chen JJ; Shen HC; Rivera Rosado LA; Zhang Y; Di X; Zhang B
    Oncotarget; 2012 Aug; 3(8):833-42. PubMed ID: 22909995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in human basophils by anti-Fas antibody treatment in vitro.
    Matsumoto K; Maeda A; Bochner BS; Wakiguchi H; Saito H
    Int Arch Allergy Immunol; 2008; 146 Suppl 1():40-6. PubMed ID: 18504406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
    Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
    Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.
    Ifeadi V; Garnett-Benson C
    PLoS One; 2012; 7(2):e31762. PubMed ID: 22389673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression.
    Contassot E; Kerl K; Roques S; Shane R; Gaide O; Dupuis M; Rook AH; French LE
    Blood; 2008 May; 111(9):4780-7. PubMed ID: 18314443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
    Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
    Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
    Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
    Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation.
    Bachmann F; Buechner SA; Wernli M; Strebel S; Erb P
    J Invest Dermatol; 2001 Jul; 117(1):59-66. PubMed ID: 11442750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of TRAIL receptors using monoclonal antibodies.
    Griffith TS; Rauch CT; Smolak PJ; Waugh JY; Boiani N; Lynch DH; Smith CA; Goodwin RG; Kubin MZ
    J Immunol; 1999 Mar; 162(5):2597-605. PubMed ID: 10072501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma.
    Gaertner F; Krüger S; Röder C; Trauzold A; Röcken C; Kalthoff H
    Histol Histopathol; 2019 May; 34(5):491-501. PubMed ID: 30375637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.